drugset / Trial / NCT07831863

A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy

NCT07831863 ↗

Phase 3 Not yet recruiting 600 enrolled Mabwell (Shanghai) Bioscience Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy and safety of 7MW3711 versus docetaxel in patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) .

Timeline

Start
2026-10
Primary completion
2029-03
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 7MW3711 Other / unclassified — Intravenous
Comparator Docetaxel Small molecule — Intravenous